Clinical trial NCT05492799: Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE
Official title: Open-Label Multicenter Extension Study to Further Evaluate Safety, Tolerability and Efficacy of Intracerebroventricular AX 250 Treatment in Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B) Patients
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: PHASE4
Conditions: MPS III B
Lead sponsor: Allievex Corporation
Sponsor class: INDUSTRY
First posted: 2022-08-09
Enrollment: 15
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 3B/4, multicenter, multinational, open label study to further evaluate intracerebroventricular (ICV) delivered AX 250 treatment in MPS IIIB subjects that complete Study 250-202 for up to an additional 3 years (144 weeks) of treatment with AX 250 administered by ICV infusion every other week. Subjects will be evaluated for neurocognitive function, communication, adaptive behavior, quality of life, imaging characteristics and biochemical markers of disease burden. Safety will be assessed by adverse events, clinical labs, and physical exams.


Eligibility criteria: Inclusion Criteria:

1. Must have completed 240 weeks of Study 250-202 and enter 250-401 within 8 weeks of dosing completion.
2. Provides written informed consent from parent or legal guardian and assent from subject, if required
3. Has the ability to comply with protocol requirements in the opinion of the investigator
4. If female with childbearing potential, must have a negative pregnancy test at the Screening visit and be willing to have additional pregnancy tests during the study

Exclusion Criteria:

1. Has (1) a cognitive age equivalent (AEq ) score ≤ 18 months, (2) a development quotient (DQ) score ≤ 20, and (3) no evidence of improvement during the 250-202 study in secondary or exploratory efficacy endpoints
2. Would not benefit from enrolling in the study in the opinion of the investigator
3. Has received stem cell, gene therapy or enzyme replacement therapy (other than AX 250) for MPS IIIB
4. Has a history of poorly controlled seizure disorder
5. Is prone to complications from ICV drug administration including patients with hydrocephalus or ventricular shunts
6. Has received any investigational medication within 30 days prior to the Baseline visit or is scheduled to receive any investigational drug during the course of the study
7. Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with protocol requirements, the subject's well-being or safety, or the interpretability of the subject's clinical data

Primary outcomes:
measure: Primary - neurocognition
timeFrame: baseline to 144 weeks of treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Oakland
country: United States
facility: UCSF Benioff Children's Hospital Oakland
state: California
city: Pittsburgh
country: United States
facility: UPMC Children's Hospital Pittburgh
state: Pennsylvania
city: Bogotá,
country: Colombia
facility: Fundación Cardio Infantil - Instituto de Cardiología
city: Hamburg
country: Germany
facility: University Medical Center Hamburg-Eppendorf
city: Ankara
country: Turkey
facility: Gazi University Faculty of Medicine
city: London
country: United Kingdom
facility: Great Ormond Street Hospital For Children, NHS Foundation Trust
Study officials:
affiliation: Allievex Corporation
name: Medical Director
role: STUDY_DIRECTOR
References: